FTC: Hikma Must Give Up 3 Generics For Roxane
This article was originally published in Scrip
Executive Summary
The Federal Trade Commission (FTC) told Hikma Pharmaceuticals PLC it had to sell two generic drugs and give up the rights to a third to settle charges the firm's proposed $2bn acquisition of Boehringer Ingelheim GmbH unit Roxane Laboratories Inc. is anticompetitive.